PanTheryx recently debuted its new patent-pending bovine colostrum formulation of ColostrumOn at SupplySide West. The new proprietary product is shown to increase protection of Immunoglobulin G (IgG), immune and growth factors as they enter the digestive tract.
In a study published in the journal PLOS ONE, the colostrum delivered 160% more immune bioactives than other colostrum products, resulting in twice the immune protection, and three times stronger protection against GI inflammation in an in vivo model. The study also shoed ColostrumOne Extra Strength’s ability to protect against intestinal damage and inflammation.
“Colostrum faces tough conditions in the stomach and small intestines as it works to support and protect the body’s digestive and immune systems,” explained Mike Weiser, PhD, senior director of R&D and Innovation at PanTheryx, and study co-author. “We developed our new ColostrumOne Extra Strength with a unique matrix technology to protect the bioactive components of colostrum and to enhance bioavailability. Through an in vivo model focused on intestinal damage, ColostrumOne Extra Strength actively helped to create a healthier intestinal structure, especially during a time of heightened inflammation.”
ColostrumOne Extra Strength is available in bulk powder format, or as a finished consumer good in capsules, tablets and sachets.
To hear more about PanTheryx’s latest product and the science behind it, watch the full interview.
